The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $271.39 in the prior trading day, CME Group Inc (NASDAQ: CME) closed at $271.61, up 0.08%. In other words, the price has increased by $0.08 from its previous closing price. On the day, 3.29 million shares were traded. CME stock price reached its highest trading level at $273.16 during the session, while it also had its lowest trading level at $269.403.
Ratios:
Our goal is to gain a better understanding of CME by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 46.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.83. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.02. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.13.
On April 08, 2025, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $301.
Raymond James Upgraded its Mkt Perform to Outperform on March 10, 2025, while the target price for the stock was maintained at $287.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 26 ’25 when Cutinho Sunil sold 11,896 shares for $271.47 per share. The transaction valued at 3,229,444 led to the insider holds 17,440 shares of the business.
SUNIL CUTINHO bought 11,896 shares of CME for $3,229,452 on Aug 26 ’25. On Aug 18 ’25, another insider, JAMES NEWSOME, who serves as the Director of the company, bought 32,468 shares for $6.16 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CME now has a Market Capitalization of 97882808320 and an Enterprise Value of 99557359616. As of this moment, CME’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.29, and their Forward P/E ratio for the next fiscal year is 23.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.19 while its Price-to-Book (P/B) ratio in mrq is 3.52. Its current Enterprise Value per Revenue stands at 15.477 whereas that against EBITDA is 21.895.
Stock Price History:
The Beta on a monthly basis for CME is 0.44, which has changed by 0.26259756 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, CME has reached a high of $290.79, while it has fallen to a 52-week low of $202.08. The 50-Day Moving Average of the stock is -1.51%, while the 200-Day Moving Average is calculated to be 5.70%.
Shares Statistics:
The stock has traded on average 2.28M shares per day over the past 3-months and 2001130 shares per day over the last 10 days, according to various share statistics. A total of 359.65M shares are outstanding, with a floating share count of 358.83M. Insiders hold about 0.43% of the company’s shares, while institutions hold 91.11% stake in the company. Shares short for CME as of 1755216000 were 5080621 with a Short Ratio of 2.37, compared to 1752537600 on 4728942. Therefore, it implies a Short% of Shares Outstanding of 5080621 and a Short% of Float of 1.4099999.
Dividends & Splits
In the trailing 12 months, CME’s forward annual dividend rate was 4.8, compared to 4.74 this year. Against a Trailing Annual Dividend Yield of 0.017686723The stock’s 5-year Average Dividend Yield is 3.44. The current Payout Ratio is 107.52% for CME, which recently paid a dividend on 2025-06-09 with an ex-dividend date of 2025-09-09. Stock splits for the company last occurred on 2012-07-23 when the company split stock in a 5:1 ratio.
Earnings Estimates
The market rating for CME Group Inc (CME) is a result of the insights provided by 15.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $2.69, with high estimates of $2.87 and low estimates of $2.57.
Analysts are recommending an EPS of between $11.53 and $10.86 for the fiscal current year, implying an average EPS of $11.15. EPS for the following year is $11.61, with 18.0 analysts recommending between $12.14 and $10.96.
Revenue Estimates
11 analysts predict $1.58B in revenue for the current quarter. It ranges from a high estimate of $1.68B to a low estimate of $1.48B. As of the current estimate, CME Group Inc’s year-ago sales were $1.58BFor the next quarter, 11 analysts are estimating revenue of $1.6B. There is a high estimate of $1.7B for the next quarter, whereas the lowest estimate is $1.55B.
A total of 16 analysts have provided revenue estimates for CME’s current fiscal year. The highest revenue estimate was $6.71B, while the lowest revenue estimate was $6.41B, resulting in an average revenue estimate of $6.52B. In the same quarter a year ago, actual revenue was $6.13BBased on 16 analysts’ estimates, the company’s revenue will be $6.81B in the next fiscal year. The high estimate is $7.27B and the low estimate is $6.48B.
